- By ICR Secretariat
- Posted Monday, April 17, 2023
Avacta doses first patient in pivotal phase 1a trial
https://www.pharmatimes.com/news/avacta_doses_first_patient_in_pivotal_phase_1a_trial_1490431
Avacta – a company developing targeted oncology drugs and diagnostics – has announced that the first individual has been dosed with its AVA6000 candidate.
The oldest independent membership-led professional body for clinical researchers across the globe.
Latest Posts
- Future of Intercept’s NASH drug in doubt after FDA panel rejection 30/05/2023 03:56 PM
- 'The Top Line': 2023's biopharma layoffs, plus this week's headlines 30/05/2023 03:55 PM
- How the digital front door benefits clinical trial patients, clinicians and sponsors 30/05/2023 03:53 PM
Useful Links
Contact Us
Suite 11a, Cedar Court
Grove Park
White Waltham
Maidenhead
SL6 3LW
info@icr-global.org